Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies

Perron, Megan; Tarshish, Gabriel; Wahezi, Dawn M.

doi:10.1186/s12969-021-00574-6

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that patients in black and Hispanic populations may have more complications related to JDM (19,20) and were disproportionately impacted by the COVID-19 pandemic with higher risk for poor physical and mental health outcomes (7,21), our study may be inadvertently biased to those with less severe outcomes. Larger investigation into a more diverse patient population would be bene cial in further evaluating these results.…”

Section: Discussionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

Wahezi

2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Throughout the COVID-19 pandemic, there have been concerns regarding the risks of infection in patients with autoimmune disease. In this study, we investigated the impact of the pandemic on patients with juvenile idiopathic inflammatory myopathies (JIIM). Methods: Data were collected using a patient/caregiver survey via Research Electronic Data Capture (REDCap) database. Eligibility included JIIM diagnosis and current age less than 21 years old. Surveys were distributed via the CureJM organization, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board. Results: Eighty-four respondents accessed the survey, 70 (83%) consented to participate, and 54 out of 70 completed the full survey (77%). Twenty-seven out of 57 patients (47%) tested positive for COVID-19, with 7 (12%) testing positive more than once. Despite broad usage of immunosuppressive medications, 24 out of 27 (89%) reported mild symptoms with none requiring hospitalization. Four patients reported a flare of JIIM symptoms after COVID-19; three of whom held immunomodulatory medications during their infection. Thirty-seven out of 54 respondents (69%) reported vaccination against COVID-19, with 9 out of 37 (24%) reporting minor vaccine side effects and one reporting JIIM flare post vaccination. Twenty-one out of 54 (39%) respondents reported psychosocial concerns related to the COVID-19 pandemic. Conclusions: Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

Wahezi

2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, the respondents for this survey were made up of predominantly white and non-Hispanic patients, with 10% of respondents reporting black race and 31% reporting Hispanic ethnicity. Given that patients in black and Hispanic populations may have more complications related to JDM [ 19 , 20 ] and were disproportionately impacted by the COVID-19 pandemic with higher risk for poor physical and mental health outcomes [ 7 , 21 ], our study may be inadvertently biased to those with less severe outcomes. Larger investigation into a more diverse patient population would be beneficial in further evaluating these results.…”

Section: Discussionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

Wahezi,

Jerome,

Rothschild

et al. 2023

Pediatr Rheumatol

Self Cite

View full text Add to dashboard Cite

Background Throughout the COVID-19 pandemic, there have been concerns regarding the risks of infection in patients with autoimmune disease. In this study, we investigated the impact of the pandemic on patients with juvenile idiopathic inflammatory myopathies (JIIM). Methods Data were collected using a patient/caregiver survey via Research Electronic Data Capture (REDCap) database. Eligibility included JIIM diagnosis and current age less than 21 years old. Surveys were distributed via the CureJM organization, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board. Results Eighty-four respondents accessed the survey, 70 (83%) consented to participate, and 54 out of 70 completed the full survey (77%). Twenty-seven out of 57 patients (47%) tested positive for COVID-19, with 7 (12%) testing positive more than once. Despite broad usage of immunosuppressive medications, 24 out of 27 (89%) reported mild symptoms with none requiring hospitalization. Four patients reported a flare of JIIM symptoms after COVID-19; three of whom held immunomodulatory medications during their infection. Thirty-seven out of 54 respondents (69%) reported vaccination against COVID-19, with 9 out of 37 (24%) reporting minor vaccine side effects and one reporting JIIM flare post vaccination. Twenty-one out of 54 (39%) respondents reported psychosocial concerns related to the COVID-19 pandemic. Conclusions Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.

show abstract

“…We have already mentioned that there was a difference between the prevalence of anti-synthetase antibodies in the Indian population and in the UK [21,28]. Besides that, research has demonstrated higher prevalence of antibodies and ILD in patient of Black or Hispanic descent [21,33].…”

Section: Adults Childrenmentioning

confidence: 97%

Clinical and autoantibody phenotypes of juvenile dermatomyositis

Boyarchuk¹,

Kuka²,

Yuryk³

2022

Reumatologia

View full text Add to dashboard Cite

Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune inflammatory myositis with symmetrical proximal muscle weakness and a characteristic rash. Juvenile dermatomyositis is characterized by variable presentation and phenotypes. Detection of myositis autoantibodies is useful in improving JDM diagnosis and predicting the prognosis. In this literature review based on case series we analyze clinical and autoantibody phenotypes of JDM in four patients who were hospitalized in one regional center in Ukraine during the last 3 years and three of them presented in the time of the COVID-19 pandemic. The reviewed literature showed the last updates for the JDM diagnosis and the role of myositis autoantibodies in the prediction of disease course, systemic involvement, and malignancy risk. The presence of anti-synthetase syndrome in all presented patients, mainly due to anti-PL-7 autoantibodies, encourages further study with more patients and with detection of other myositis-specific autoantibodies to identify or refute certain regional features.

show abstract

Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies

Cited by 7 publications

References 12 publications

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies

Clinical and autoantibody phenotypes of juvenile dermatomyositis

Contact Info

Product

Resources

About